Frequently Asked Questions

Average Sales Price (ASP) Reimbursement

Frequently Asked Questions (FAQs)

 

In December 2016, Congress passed the 21st Century Cures Act. The Cures Act contains a provision that changes the payment structure for infusion drugs under the Medicare Part B Durable Medical Equipment (DME) benefit from an Average Wholesale Price (AWP) metric to an Average Sales Price (ASP) payment methodology. The move from AWP to ASP took effect on January 1, 2017. Below are answers to questions NHIA has received regarding the new way Part B DME drugs are reimbursed.  If you have questions about ASP reimbursement, please email NHIA.

 

(FAQs as of 1/4/17)

 

NHIA Members click here for the FAQs.

 

Copyright ©2017 National Home Infusion Association

National Home Infusion Association

100 Daingerfield Road

Alexandria, VA 22314

703.549.3740

Frequently Asked Questions

Copyright ©2017 National Home Infusion Association